Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others); Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)); Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy)
Publication Month: Apr 2020 | Report Code: TIPRE00010407 | No. of Pages: 177 | Category: Pharmaceuticals | Status: Published
The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027.
Liposomes, a novel drug delivery system (NDDS), are bilayer vesicular structures used in delivering drugs or genetic material into a cell. The aim of NDDS is to deliver the drug at a rate directed by the needs of the body during the period of treatment. Due to the growing number of COVID-19 patients, especially in the US and the European countries, research institutes are pressurized to accelerate their R&D activities to develop drugs and vaccines for the treatment. Thus, companies in the liposome drug delivery market are capitalizing on this opportunity to increase their research in nanomaterials, such as nanospheres, liposomes, and nanoparticles that are active antiviral agents. Liposome drug delivery is being leveraged with increased in vivo and in vitro drug activities for routine clinical practices.
Lucrative Regions for Liposome Drug Delivery Market
Get more information on this report :
Market Insights
Increasing Prevalence of Chronic Diseases
Over the past few decades, R&D activities in liposomal drug delivery systems have rapidly increased across the world due to increasing prevalence of chronic disease. Drug delivery is the process of administering a pharmaceutical compound to achieve a therapeutic effect in humans. Liposomal drug delivery offers various advantages, such as improved pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity, thereby making these delivery systems ideal for patients suffering from various chronic conditions. According to the Centers for Disease Control and Prevention (CDC) in 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.
Cancer is one of the leading causes of death among population worldwide. The American Cancer Society (ACS) estimated that ~1,735,350 new cancer cases were diagnosed in 2018. Targeted drug delivery system (TDDS) delivers the drug in a controlled manner at a preselected biosite. Nanotechnology-based delivery systems are making a significant impact on cancer treatment and the polymers play a key role in the development of nanoparticulate carriers for cancer therapy. A few major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of drug, and many more. The liposomal carriers utilized in nanotechnology drug delivery systems are likely to experience rapid adoption, which, in turn, is propel the market growth.
Product -Based Market Insights
The liposome drug delivery market, based on product, is segmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. In 2019, the liposomal doxorubicin accounted for the largest share by product owing to the high efficacy of the drug exhibited in the treatment of cancer. Moreover, the liposomal doxorubicin is beneficial over its traditional counterpart in terms of toxicity and targeted drug delivery. The drug also exhibits significant recovery among patients suffering with HIV-related Kaposi’s sarcoma and multiple myeloma.
Global Liposome Drug Delivery Market, by Product– 2019 and 2027
Get more information on this report :
Technology-Based Market Insights
Based on technology, the liposome drug delivery market is segmented into stealth liposome technology, non-PEGylated liposome technology, DepoFoam liposome technology. The stealth liposome technology segment held the largest share of the market in 2019 and is likely to continue to register the highest CAGR in the market during the forecast period.
Application-Based Market Insights
Based on technology, the liposome drug delivery market is segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. The cancer therapy segment held the largest share of the market in 2019 and is likely to continue to register the highest CAGR in the market during the forecast period.
Strategic Insights
Partnerships, agreements, and acquisitions are the most commonly adopted strategies by companies to expand their footprints worldwide and meet the growing demand. The market players most commonly adopt these strategies to expand their geographic presence and product portfolio.
For instance, in April 2019, Ipsen Pharma completed its acquisition of global oncology assets from Merrimack Pharmaceuticals, Cambridge that focuses on ONIVYDE (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Global Liposome Drug Delivery Market – By Product
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphotericin B
- Others
Global Liposome Drug Delivery Market – By Technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome (LTSL) Technology
Global Liposome Drug Delivery Market – By Application
- Fungal Diseases
- Cancer Therapy
- Pain Management
- Viral Vaccines
- Photodynamic Therapy
Liposome Drug Delivery Market – By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
Asia Pacific
- China
- India
- South Korea
- Japan
- Australia
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
South and Central America
- Brazil
- Argentina
Company Profiles
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Luye Pharma Group
- Ipsen Pharma
- CELSION, Inc.
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- Johnson & Johnson Services, Inc.
- Acrotech Biopharma, Inc.
The List of Companies - Liposome Drug Delivery Market
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Luye Pharma Group
- Ipsen Pharma
- CELSION, Inc.
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- Johnson & Johnson Services, Inc.
- Acrotech Biopharma, Inc.
- Pacira Biosciences, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the liposome drug delivery market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global liposome drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Get the Latest COVID-19 Analysis on this market
Have a Question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
-
$3000
-
$4550 $3640
-
$6550 $5240
-
$8550 $6840
-
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount